icon
icon
icon
icon
Upgrade
icon

AstraZeneca's (AZN.US) Phase III study for chronic sinusitis with nasal polyps met its primary endpoint

AInvestFriday, Nov 8, 2024 8:10 am ET
1min read

AstraZeneca (AZN.US) announced that the Phase III WAYPOINT study of Tezspire (tezepelumab) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) met its co-primary endpoints. The results showed a statistically significant and clinically meaningful reduction in nasal polyp size and improvement in nasal congestion symptoms in the Tezepelumab treatment group.

Public information shows that Tezepelumab is a first-in-class monoclonal antibody co-developed by AstraZeneca and Amgen, which inhibits thymic stromal lymphopoietin (TSLP). TSLP is a key epithelial cytokine located upstream of multiple inflammatory cascades and is associated with diseases such as asthma, CRSwNP, chronic obstructive pulmonary disease (COPD), and eosinophilic esophagitis (EoE). Tezspire blocks TSLP, thereby preventing immune cells from releasing pro-inflammatory cytokines, achieving therapeutic effects for related diseases.

It is known that Tezepelumab has been approved in the US for the treatment of severe asthma, and its Phase III clinical study is ongoing in China. In addition to CRSwNP, Tezepelumab is being developed for other potential indications, including COPD and EoE.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.